Since anti-EGFR targeted therapies such as cetuximab and panitunumab improve tumor response when used in combination with irinotecan in colorectal cancer [46, 47], it will be interesting to determine the effect of the EGF pathway and of these antibodies on PLCs emergence. The gene discussed is EGF; the disease is neoplasm.